RVP-001
General Purpose MRI Contrast Enhancement
Phase 2Active
Key Facts
Indication
General Purpose MRI Contrast Enhancement
Phase
Phase 2
Status
Active
Company
About Reveal Pharmaceuticals
Reveal Pharmaceuticals is pioneering the development of gadolinium-free MRI contrast agents and first-in-class fibrogenesis imaging agents. Its lead candidate, RVP-001, is a manganese-based agent in Phase 2 clinical studies with FDA Fast Track designation, targeting the 65-million-dose-per-year global MRI contrast market. The company is led by an experienced team with deep expertise in radiology and contrast agent development and is backed by over $17M in NIH and other grants. Reveal aims to displace current gadolinium-based agents by offering a safer alternative for patients and reducing environmental pollution and supply chain vulnerabilities.
View full company profile